文献速递流行病学与生物统计真实世界研究与卫生经济

美国公共资助患者导航干预改善HIV照护连续体结局与成本:前后对照研究

Outcomes and costs of publicly funded patient navigation interventions to enhance HIV care continuum outcomes in the United States: A before-and-after study.
PubMed 文献 · PLoS Med · 2021-05-13

本研究采用前后对照设计,评估美国5个州级示范项目利用监测和/或临床数据识别未入组、脱失或面临脱失风险的HIV患者,并通过患者导航干预改善照护连续体结局与成本。共入组3,443例患者,所有干预均与病毒抑制比例提升相关,每额外实现一例病毒抑制的追加成本各州不同。

要点

  • 患者导航干预与HIV照护参与和病毒抑制改善相关。
  • 利用监测数据识别脱失患者可能降低每结局成本。
  • 各州每额外病毒抑制病例追加成本为920至4,415美元。

核心结论

  • 患者导航项目与HIV照护参与和病毒抑制改善相关。
  • 利用监测数据识别脱失患者或基线需改善患者较多的州,每结局成本更低。

研究设计与样本

  • 前后对照设计,评估5个州级示范项目(LA、MA、NC、VA、WI)在2013至2014年实施首年的结局与成本。
  • 共入组3,443例患者,平均40岁,75%男性,69%非洲裔美国人,22%白人。

主要发现

  • 所有5个干预均与病毒抑制患者数量和比例增加相关。
  • 病毒抑制比例增幅:LA=90.9%(95%CI 88.4至93.4),MA=78.1%(95%CI 72.4至83.8),NC=47.5%(95%CI 45.2至49.8),VA=54.6%(95%CI 49.4至59.9),WI=58.4%(95%CI 53.4至63.4)。

关键数值与推荐

  • 每额外实现一例病毒抑制的追加成本:LA=4,415美元(范围3,746至5,619),MA=2,009美元(范围1,516至2,274),NC=920美元(范围627至941),VA=2,212美元(范围1,789至2,683),WI=3,700美元(范围2,734至4,101)。

临床怎么用

  • 患者导航干预可用于改善HIV照护连续体结局。
  • 利用监测和临床数据识别需干预患者可能优化项目成本效果。

局限性

  • 缺乏同期对照,仅能比较患者自身基线,无法与同期标准照护对比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the United States, patients with HIV face significant barriers to linkage to and retention in care which impede the necessary steps toward achieving the desired clinical outcome of viral suppression. Individual-level interventions, such as patient navigation, are evidence based, effective strategies for improving care engagement. In addition, use of surveillance and clinical data to identify patients who are not fully engaged in care may improve the effectiveness and cost-effectiveness of these programs. METHODS AND FINDINGS: We employed a pre-post design to estimate the outcomes and costs, from the program perspective, of 5 state-level demonstration programs funded under the Health Resources and Services Administration's Special Projects of National Significance Program (HRSA/SPNS) Systems Linkages Initiative that employed existing surveillance and/or clinical data to identify individuals who had never entered HIV care, had fallen out of care, or were at risk of falling out of care and navigation strategies to engage patients in HIV care. Outcomes and costs were measured relative to standard of care during the first year of implementation of the interventions (2013 to 2014). We followed patients to estimate the number and proportion of additional patients linked, reengaged, retained, and virally suppressed by 12 months after enrollment in the interventions. We employed inverse probability weighting to adjust for differences in patient characteristics across programs, missing data, and loss to follow-up. We estimated the additional costs expended during the first year of each intervention and the cost per outcome of each intervention as the additional cost per HIV additional care continuum target achieved (cost per patient linked, reengaged, retained, and virally suppressed) 12 months after enrollment in each intervention. In this study, 3,443 patients were enrolled in Louisiana (LA), Massachusetts (MA), North Carolina (NC), Virginia (VA), and Wisconsin (WI) (147, 151, 2,491, 321, and 333, respectively). Patients were a mean of 40 years old, 75% male, and African American (69%) or Caucasian (22%). At baseline, 24% were newly diagnosed, 2% had never been in HIV care, 45% had fallen out of care, and 29% were at risk of falling out of care. All 5 interventions were associated with increases in the number and proportion of patients with viral suppression [percent increase: LA = 90.9%, 95% confidence interval (CI) = 88.4 to 93.4; MA = 78.1%, 95% CI = 72.4 to 83.8; NC = 47.5%, 95% CI = 45.2 to 49.8; VA = 54.6, 95% CI = 49.4 to 59.9; WI = 58.4, 95% CI = 53.4 to 63.4]. Overall, interventions cost an additional $4,415 (range = $3,746 to $5,619), $2,009 (range = $1,516 to $2,274), $920 (range = $627 to $941), $2,212 (range = $1,789 to $2,683), and $3,700 ($2,734 to $4,101), respectively per additional patient virally suppressed. The results of this study are limited in that we did not have contemporaneous controls for each intervention; thus, we are only able to assess patients against themselves at baseline and not against standard of care during the same time period. CONCLUSIONS: Patient navigation programs were associated with improvements in engagement of patients in HIV care and viral suppression. Cost per outcome was minimized in states that utilized surveillance data to identify individuals who were out of care and/or those that were able to identify a larger number of patients in need of improvement at baseline. These results have the potential to inform the targeting and design of future navigation-type interventions.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Shade SB, Kirby VB, Stephens S, et al. Outcomes and costs of publicly funded patient navigation interventions to enhance HIV care continuum outcomes in the United States: A before-and-after study. PLoS Med. 2021. PMID: 33983925. doi:10.1371/journal.pmed.1003418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。